Calgary, Alberta – TheNewswire - June 2, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce that the first-in-human (FIH) clinical study for its revolutionary accommodating intraocular lens (the “Ocumetics Lens”) will take place in Mexico City.  This follows a strategic decision to relocate the study from its originally planned site in the Dominican Republic that will allow Ocumetics to take advantage of resources that better meet the Company’s needs.

 

Dean Burns, CEO of Ocumetics commented, “The Ocumetics team demonstrated outstanding agility and professionalism in managing the site relocation.  After a detailed analysis of alternative sites and their resources, we chose a site in Mexico City because it meets all protocol requirements and offers a strong foundation for clinical studies.  Mexico City provides an ideal environment for this pivotal study with clinicians experienced in investigational studies, and an advanced infrastructure capable of supporting high-caliber ophthalmic research.”

 

Dr. Garth Webb, Founder and Chief Scientific Officer added: “With Mexico City now confirmed as the site for our first-in-human studies, we remain fully committed to moving forward with momentum and clinical rigor.  This milestone brings us one step closer to validating the Ocumetics Lens in a real-world clinical setting.”

 

Preparations are currently underway to activate the clinical site in Mexico City, including staff training, regulatory submissions, and logistical planning.  Ocumetics remains on track to begin human implantation of its novel accommodative intraocular lens in the summer of 2025.

About Ocumetics

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients.  Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.

Ocumetics is in the preclinical study stage of a game-changing technology for the ophthalmic industry.  Ocumetics has developed an intraocular lens that fits within the natural lens compartment of the eye potentially to eliminate the need for corrective lenses.  It is designed to allow the eye’s natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.  

 

FOR FURTHER INFORMATION, PLEASE CONTACT:

 

Dean Burns                                Roger Jewett

President and CEO                        Chief Financial Officer

(817) 874-7564                                roger.jewett@ocumetics.com

 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation.  Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the research and development to be conducted by the Corporation mentioned above.  Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances.  There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.  The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.